Skip to content

Conflict of Interest

Faculty Conflict of Interest (Aggregate)

Joyce O’Shaughnessy MD

 

Received honoraria for consulting and advisory boards:

AbbVieInc.

Agendia

AmgenBiotechnology

AstraZeneca

Bristol-Myers Squibb

CelgeneCorporation

Eisai

Genentech

Genomic Health

GRAIL

Immunomedics

Heron Therapeautics

Ipsen Biopharmaceuticals

Jounce Therapeutics

Lilly

Merck

Myriad

Novartis

Ondonate Therapeutics

Pfizer

Puma Biotechnology

Prime Oncology

Roche

Seattle Genetics

Syndax Pharmaceuticals

Takeda

Terry Mamounas MD

Genentech/Roche

Exact Sciences: Consultant (Advisory Board) and member of Speaker’s Bureau

Biotheranostics, Daiichi Sankyo: Consultant (Advisory Board)

Merck: Consultant

Ramaswamy Govindan MD

Consulting

Horizon Pharmaceuticals (wife’s conflict)

GenePlus

William Gadishar MD

DSMB-

Seattle Genetics

Roche/Genentech

International Breast Cancer Study GroupNovartisAlliance Foundation DSMB

Advisory Board/Consultant

Lilly

Merck

AstraZeneca/Daicchi

Pfizer

Immunomedics

Thomas Buccholz MD

1.Scripps Health Care System –primary employment as Corporate SVP and Medical Director of Scripps MD Anderson Cancer Center, receive salary and benefits

2.Scripps Clinic Medical Group –primary employment for radiation oncology physician services, receive compensation for providing medical care

3.Abivaxpharmaceutics –data safety monitoring committee for a phase I/II trial (ongoing, receive hourly compensation for work provided)

4.Patient Resources, LLC:Medical Advisory Board (ongoing, receive annual modest compensation)

5.Breakthrough Chronic Care: Vice Chairman, Scientific Advisory Board and Board of Directors Member for their Terminator Foundation. (received stock, currently has no value) 6.Genentech/Roche scientific advisory board of a phase II trial (receivehourly compensation for work provided)

7.Roche Diagnostics –consultant for their Navify data platform (receive hourly compensation for work provided)

8.Rancho Sante Fe Community Foundation, member Board of Directors. (non-profit, no compensation)

9.PER, accepted invited speaking engagements for two CME breast cancer conferences this July, will receive honorarium for speaking.

10.Mirada –medical advisory board –uncompensated.

11.Nucleix Inc, Member Board of Directors, received stock options (liquid bx company)

12.Empyrean Medical Systems, Inc., Member Board of Directors, to receive stock options for board position and have equity interest through term sheet with MD Anderson regarding intellectual property (radiation oncology medical device company)

13.Bucknell University –Member Board of Trustees, uncompensated

14.Ultimate Opinions in Medicine LLC –receive compensation for providing medical education services and consulting

Sara Hurvitz MD

Contracted research with: Ambrx, Amgen, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana, ZymeworksConsulting: NK Max

Kristin Higgins MD

Astra Zeneca: consultant/advisory boards

Genetech: advisory board

RefleXion Medical: Funded research

Darren Kies MD

Besides my day job as a radiologist with Piedmont South Imaging, I am also a consultant with Terumo Medical Corporation as a traveling proctor for radial artery access

Suresh Ramalingam MD

I have served on scientific advisory board meetings and received honoraria from Amgen, Astra Zeneca, Bristol Myers Squibb, Merck, Glaxo SmithKline, Takeda, Genentech, Daichii Sankyo and Puma. My institution has received research support from Genmab, Advaxis, Merck, Takeda, Astra Zeneca and BMS

Clifford Robinson MD

Leadership

Radialogica

Stock and Other Ownership Interests

Radialogica

Consulting or Advisory Role

Varian Medical Systems

AstraZeneca

EMD Serono

Varian Medical Systems

Merck

Siemens Healthineers

Michael Lanuti MD

1.Consultant for Bristol Myers Squibb2.Panel Member for Non Small Cell Lung Cancer, Mesothelioma and Thymoma for National Cancer Care Network

Sanjeev Bhalla MD

I have no conflicts of interest or financial disclosures

Tari King MD

My disclosures:Speakers Honoria and Advisory Board for Exact Sciences (formerly Genomic Health)

Chirag Shah MD

Consultant = Impedimed

Consultant= PreludeDX

Grants = Varian Median Systems, VisionRT, PreludeDX

Benjamin Levy MD

Consulting: AstraZeneca, Takeda, Genentech Roche, Eli Lilly, Pfizer, Merck, Novartis

Research Funding: Turning Point, BMS, Genentech Roche, Astra Zeneca, Eli Lilly

Michelle Ginsberg MD

No Disclosures

Maxine Jochelson MD

GE: speaker

Bayer: consultant

Curran COI1.Member and Chair of a Bristol Meyers Squibb-supported Data Monitoring Committee. Member of an Astra Zeneca-supported Data Monitoring Committee

Reni Butler MD

No Disclosures

Ross Camidge MD, PhD

•Advisory role: Ad hoc advisory boards/consultations

–2020: Anchiarno(SAB), Amgen, Takeda, Roche, EMD Serono, Sanofi, Pfizer

–2019: Takeda, CBT Pharmaceuticals, Daiichi-Sankyo (ILD adjudication committee), G1 Therapeutics (DSMB), Bio-Thera (DSMB), Blueprint, Abbvie, Achilles, BeyondSpring, Apollomics(standing SRC), 14ner/Elevation (standing SRC), Archer, EMD Serono, Helssin, BMS, Eli Lilly, Medtronic, Ribon

–2018: AstraZeneca, Takeda, Arrys/Kyn, Regeneron, Hengrui, G1 Therapeutics (DSMB), DaichiiSankyo (ILD adjudication committee), Hansoh(SRC), Bio-Thera (DSMB), Ribon, BMS, Blueprint, Roche/Genentech, Inivata

•Research funding:

–2017: Takeda Investigator-initiated Trial

•Company sponsored trials at institution (PI roles): –2018-20: Abbvie, AstraZeneca, BMS, GSK, Hansoh, Inhibrx, Lycera, Medimmune, Merck, Pfizer, Phosplatin, Psioxus, Rain, Roche/Genentech, Seattle Genetics, Symphogen, Takeda, Tolero

VARUN PURI MD

I have federal grant support from:

1 I01 HX002475-01A2 (Puri)

10/1/2019-9/30/2023

Department of Veterans Affairs (HSR)

Defining Quality of Care in Lung Cancer $210,500 / year

The goal of this project is to establish quality parameters in lung cancer surgery.

1 R01 HL146856-01A1 (Puri)

7/1/2020-6/30/2024

National Heart Lung and Blood Institute

Optimizing Donor Management in Lung Transplantation

The goal of this project is to develop evidence-based algorithms for lung donor assessment.

My wife owns stock in Intuitive Surgical (da Vinci robot).

No other conflicts.Thank you

Ruth O’Regan MD

Advisor: Novartis, Lilly, Genentech, Biotheranostics, Puma, Macrogenics (all less than NIH cap)

Research support: puma, Novartis, Eisai, Pfizer

JACK WEST MD

AstraZeneca – Consultant and Speaker

Genentech/Roche – Consultant

Jazz Pharmaceuticals — Consultant

Lilly — consultant

Merck — Consultant and Speaker

Takeda — Consultant and Speaker

Martin Weiser MD

Section editor for UptoDate

David Kooby MD

No COI

Scott Celinski MD

No COI

Michael Pishvaian MD

Speaker/Consultant:

AstraZeneca/MedImmune, Perthera, Sirtex Medical, Merck, Halozyme, Foundation Medicine, Caris

Travel, accommodations, and expenses support:

AstraZeneca/MedImmune, Perthera, Sirtex Medical, Merck

Stock:

Perthera

Research funding to my institution:

Bavarian Nordic, MedImmune

Christopher Lieu MD

Research Funding: Merck

Consulting: Ipsen and HalioDX

Daniel Catenacci MD

Honoraria, research, speaking: Genentech/Roche, Seattle Genetics, Amgen, Eli Lilly, Five Prime,

Merck, BMS, Taiho, Astellas, Gritstone, Pieris, Daiichi Sankyo, Zymeworks, QED, Foundation

Medicine, Tempus, Guardant

Health, Archer, Natera

Samuel J. Klempner MD

Consulting/Advisory: Eli Lilly, Merck, BMS, Astellas, Pieris, Foundation Medicine, Natera

Stock/Equity: Turning Point Therapeutics

Other (may not need to disclose): NCCN guideline committee, medical advisory board for Hope for Stomach Cancer and Debbie’s Dream Foundation

Grant Funding: NCI, AACR-SU2C, AGA-Gastric Cancer Foundation

Christopher Crane MD

Trisalus- Consultant

Eleckta AB, Stockholm Sweden-MSKCC Research agreement, Honorarium and Travel expenses

Zev Wainberg MD

Consulting: BMS, Bayer, Five Prime, Ipsen, Merck, EMD Serono, Macrogenics, Ono,

Lilly,

Novartis, Arcus

Grants: Novartis, Plexxikon, Ipsen

Christina Wu MD

Vaccinex – Research fees to Emory Healthcare – site PI of trial

Boston Biomedical Inc – Research fees to Emory Healthcare- site PI of trial Lycera- Research fees to Emory Healthcare – site PI of trial

Seattle Genetics – Research fees to Emory Healthcare – site PI of trial

Symphogen – Research fees to Emory Healthcare – site PI of trial

Rapt Therapeutics – Research fees to Emory Healthcare – site PI of trial

INHBRX – Research fees to Emory Healthcare – site PI of trial

Array Biopharma – honorarium – consultant

Signatera – honorarium – consultant

Oncology Learning Network – honorarium – speaker

Al Benson MD

Consulting or Advisory: NCCN, BMS, Patient Resource (Educational Document Review),Research to Practice, AVBCC, Harborside, Therabionic, Guardant, Merck (DMC), Terumo, Lexicon, ACCC, ECOG – ACRIN, AMGEN, Imedex, Artemida Pharma, Intellisphere OncLiv, American college of Radiology, China National Medical Association 6th Affiliated Sun Yet – San Hospital, Springer, Health Advances:, Lexicon: 2020 Array (Pfizer) – Advisory, NCCN, ACCC, AbbVie, Tyme, IRCI, SynCore

Research: BMS-DMC, Astellas Research, Celegene, Infinity Pharmaceuticals, Merck Sharp and Dohme, Taiho Pharmaceutical, Rafael Pharmaceuticals, Medimmune/AstraZeneca, Xencor, Bristol-Myers Squibb: Data Monitoring Committee, PreECOG: Data Monitoring Committee, Astellas: Data Monitoring Committee, Amgen: Data Monitoring Committee ASCO, ECOG – ACRIN: Data Monitoring Committee, SynCore: Data Monitoring Committee

Timothy Donahue MD

I have only one COI to disclose: I am and Executive Board Member of Trethera Corporation and am compensated with stock options.

Carlos Roberto Becerra MD

Honoraria: Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical

Consulting or Advisory Role: Agenus; Agenus; Agenus; Agenus; Bayer; Bayer; Bayer; Bayer; HERON; HERON; HERON; HERON; Ipsen; Ipsen; Ipsen; Ipsen; SOBI; SOBI; SOBI; SOBI; Takeda; Takeda; Takeda; Takeda

Speakers’ Bureau: Bristol – Myers Squibb; Celgene; Merck Serono; Taiho Pharmaceutical

Cathy Eng MD

Foundation of medicine, Natera, Merck, Bayer, Abbvie

Richard Finn MD

Consultant: AstraZeneca, Bayer, BMS, Eisai, Eli Lilly, CStone, Roche/Genentech, Merck, Pfizer

Vincent Melnick MD

No COI

Cynthia Collins MD

No COI

Walter Curran MD

Member and Chair of a Bristol Meyers Squibb – supported Data Monitoring Committee Member of an Astra Zeneca – supported Data Monitoring Committee

Thomas Stinchecombe

Consulting or Advisory Role: Takeda, AstraZeneca, Genentech/Roche, Foundation Medicine, Pfizer, EMD Serono, Novartis, Daiichi Sankyo, Lilly, Medtronic, Puma Biotechnology, Janssen Oncology, Regeneron

Research Funding: Genentech/Roche, Blueprint Medicines, AstraZeneca, Takeda, Advaxis, Regeneron

Larry Kestin MD

No COI

Frank Vicini MD

Consultant for ImpediMed

Seth Force MD

consultant for Johnson and Johnson, Ethicon Division

Matt Loscalzo MD

I am a consultant for Astra Zeneca and I get Royalties from

City of Hope, my employer, as the developer of SupportScreen (an automated biopsychosocial screening and educational instrument).

Mark Pegram MD

AstraZeneca, Daiichi Sankyo, Eli Lilly (spouse), Roche/Genentech, Novartis, Pfizer, Sanofi Aventis

Ruth O’Regan MD

Advisor: Novartis, Lilly, Genentech, Biotheranostics, Puma, Macrogenics (all less than NIH cap)

Research support: puma, Novartis, Eisai, Pfizer

Anne O’Dea

Consulting/Honoriaria: PUMA Biotechnology, Pfizer, AstraZeneca, Daiichi Sankyo

Norman Wolmark MD

No COI

William Gradishar MD

DSMB: Seattle Genetics, Roche/Genentech, International Breast Cancer Study Group, Novartis, Alliance Foundation DSMB, Advisory Board/Consultant, Lilly, Merck, AstraZeneca/Daicchi, Pfizer, Immunomedics

Steven Paul Poplack MD

No COI

Monica Morrow MD

honoraria for speaking from Roche and Exact Sciences

Reshma Mahtani DO

Advisor/consultant:Agendia, Amgen, AstraZeneca, Biotheranostics, Daiichi, Eisai, Genentech, Immunomedics, Lilly, Novartis, Pfizer, Puma, Sanofi, SeaGen

Jeremy Abramson MD

Consulting for AstraZeneca, BeiGene, C4 Therapeutics, Celgene, Incyte, Morphosys.

John Pagel MD

Consultant for: BeiGene, Loxo Oncology, Gilead, Astrazeneca and Seagen.

Gary Schiller MD

PI: NMDP/CIBMTR, UCGMC, AbbVie, Actinum, Actuate, AROG, Atellas, BMS/Celgene, Celator, Constellation, DaiiChi – Sankyo, Deciphera, Delta – fly, Forma, Fugi Film, Gamida, Genentech-Roche, Geron, Incyte, Karyopharm, Gilead/Kite, Mateon, Oncanova, Pfizer, PrECOG, Regimmune, Samus, Sangamo, Semline Takeda, Tolero, Trovagene

Consultant/Speaker: Agios, Amgen, Jazz, ONO – Uk, Novartis, Sanofi,

Ajay Nooka MD

advisory boards and received consulting fees from Amgen, Bristol-Myers Squibb, Sanofi, GlaxoSmithKline, Janssen Oncology, Karyopharm Therapeutics, Oncopeptides, Adaptive and Takeda

Yi – Bin Chen MD

Consulting for Incyte

Data Monitoring Committees: Equilium, Daiichi, Abbvie, Celularity

Malani Kamdar MD

Research Support/Funding: TG Therapeutics, Genentech.

Consultancy: AbbVie, KaryoPharm, Kite, AstraZeneca, Celgene/ Bristol-Myers Squibb,

Adaptive Biotechnologies,Curio Science.

Speaker’s bureau: SeaGen

Michael Thirman MD

Consultant/Advisory Boards: AbbVie, AstraZeneca, Celgene, Janssen, Pharmacyclics, Roche/Genentech

Grant/Research/Clinical Trial Support: AbbVie, Gilead Sciences, Janssen, Merck, Pharmacyclics, Syndax, TG Therapeutics, Tolero

Daniel Pollyea MD

Consultant or Advisory Board Member for:

Karyopharm, Novartis, Syndax, Celgene, Bristol Myers Squibb, Takeda, Abbvie, Syros, Kiadis, Foghorn, Aprea, Genentech, Gilead, Astellas

David M. Schuster MD

Consultant: Syncona; AIM Specialty Health; Global Medical Solutions Taiwan; Progenics Pharmaceuticals, Inc.

Research: Participates through the Emory Office of Sponsored Projects

in full compliance with Emory University sponsored research and conflict of interest regulations in sponsored grants including those funded or partially funded by Blue Earth Diagnostics, Ltd; Nihon MediPhysics Co, Ltd.; Telix Pharmaceuticals (US) Inc.; Advanced Accelerator Applications; FUJIFILM Pharmaceuticals U.S.A., Inc; AmgenInc. Educational: School of Breast Oncology;PrecisCa

Peter Forsberg MD

Honoraria for speakers bureau activities: Celgene/BMS

Research funding:Karyopharm, Genentech, Amgen, Sanofi

Maha Hussain MD

Receiving grant support, advisory board fees, and travel support from Pfizer, Bayer, and Genentech/Roche, grant support, advisory board fees, and lecture fees from AstraZeneca, grant support from ARVINAS, lecture fees and travel support from Astellas, lecture fees from Physicians’ Education Resource, Sanofi/Genzyme, and Research to Practice, honoraria from Projects in Knowledge, advisory board fees from BMS and Daiichi Sankyo, holding patents UM-14437/US-1/PRO 60/923,385 and UM-14437/US-2/ORD12/101,753 on systems and methods for tissue imaging, patent 224990/10-016P2/31173361/481/671 on a method of treating cancer, and patent 11764665.4-1464 on dual inhibition of MET and VEGF for the treatment of castrati on resistant prostate cancer and osteoblastic bone metastases;

Matthew Rettig MD

Research Grant: Novartis, Johnson & Johnson, Merck, Astellas, Medivation

Member, Speakers Bureau: J&J, Bayer

Consultant: Amgen, Ambrx, Constellation Pharmaceuticals

Jason Abel MD

Genzyme Advisory Board

Cary Siegel MD

No COI

Susan Slovin MD

Honoraria for advisory boards and educational programs from: Novartis, Janssen, Pfizer, Clovis and Physician Education Resource Research Funding from: Sanofi-Aventis, Novartis, Poseida Pharma

Mehmet Asim Bilen MD

consultant for and/or as a member of the advisory boards of Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Genomic Health, Nektar, and Sanofi and has received grants to his institution from Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, Seattle Genetics, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Peleton Therapeutics, and Pfizer for work performed as outside of the current study

Alexandra Drakaki MD

Employment/Stock: Athos Therapeutics, Attica Sciences, Dyania

Honoraria: Kite Pharma

Travel expenses: Seattle Genetics, Eli Lilly, Astra Zeneca

Tyler Fraum MD

Consultant: Arterys Inc.

Research Support: Siemens AG

Pretesh Patel MD

No COI

Aarti Sekhar MD

No COI

Brian Rini MD

Research Funding to Institution: Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis

Consulting: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Arravive, Alkermes, Arrowhead, GSK, Shionogi, MEI pharma

Stock: PTC therapeutics

 

Heather McArthur, MD

Dr. McArthur has consulted for Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Pfizer, Puma,  Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Peregrine, Calithera, Daiichi-Sankyo, Seattle Genetics, AstraZeneca, Gilead, Crown Bioscience, and TapImmune.

 

Dr. McArthur has research supported by Bristol-Myers Squibb; MedImmune, LLC/AstraZenica; BTG; and Merck.